BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago
ADVERTISEMENT
AlphaGraphs

Merck (MRK) Earnings: 4Q22 Key Numbers

Merck (NYSE: MRK) reported fourth quarter 2022 earnings results today. Sales increased 2% year-over-year to $13.8 billion. GAAP net income fell 17% to $3 billion, or $1.18 per share, last year. Adjusted EPS dropped 7% to $1.62. For FY2023, Merck expects revenue of $57.2-58.7 billion and adjusted EPS of $6.80-6.95. Prior performance

$MRK February 2, 2023 1 min read

Merck (NYSE: MRK) reported fourth quarter 2022 earnings results today.

Sales increased 2% year-over-year to $13.8 billion.

GAAP net income fell 17% to $3 billion, or $1.18 per share, last year. Adjusted EPS dropped 7% to $1.62.

For FY2023, Merck expects revenue of $57.2-58.7 billion and adjusted EPS of $6.80-6.95.

Prior performance

Merck Q3 2022 earnings infographic
ADVERTISEMENT